3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
7
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Recurrence
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Esophageal Neoplasms
2
Burkitt Lymphoma
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Optic Nerve Glioma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Immunoblastic
1
Interventions
Sorafenib
3
atezolizumab
2
Radiotherapy
2
Bevacizumab
2
tremelimumab
1
temsirolimus
1
lonafarnib
1
liposomal doxorubicin
1
infigratinib
1
gadolinium ethoxybenzyl DTPA
1
fludarabine
1
durvalumab
1
cabozantinib
1
bavituximab
1
aldesleukin
1
Thoracoscopy
1
Thoracic Surgery, Video-Assisted
1
Resveratrol
1
Radiosurgery
1
Radionuclide Generators
1
Radiofrequency Ablation
1
Polymerase Chain Reaction
1
Oxaliplatin
1
Nivolumab
1
NSC 366140
1
Mass Spectrometry
1
Immunotherapy
1
Immunohistochemistry
1
Genetic Testing
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Liver Neoplasms
×
Drug Therapy
×
Clear all
NCT00510627
2017-03-03
Prometheus
Boston Scientific Corporation
Phase 4
Withdrawn